Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) achieves key objective as the United States District Court for the District of Delaware denies CareDx’s motion for summary judgment on two Natera patents in an infringement lawsuit. The trial will commence on January 22, 2024, as Natera aims to protect its significant investments in innovation from unlawful infringement.

Positive

• United States District Court denies CareDx’s motion for summary judgment on two Natera patents
• Natera successfully invalidated all three of CareDx’s patents in a related case

Negative

• None.

Natera successfully achieves key objective for trial set to begin on Jan. 22nd

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.

The Court has ruled that two of the patents asserted by Natera against CareDx will proceed to trial. The trial will commence on January 22, 2024.

The company stated: “We are gratified that the Court has issued a decision that provides a clear path to trial as we work to protect our significant investments in innovation from unlawful infringement.”

As previously disclosed, Natera successfully invalidated all three of CareDx’s patents that were asserted against Natera in a related case.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights, and our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231211868061/en/

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Source: Natera, Inc.

FAQ

What is the latest update from Natera, Inc. (NASDAQ: NTRA)?

Natera, Inc. (NASDAQ: NTRA) has achieved a key objective as the United States District Court for the District of Delaware denies CareDx’s motion for summary judgment on two Natera patents in an infringement lawsuit. The trial will commence on January 22, 2024.

What is the significance of the recent announcement by Natera, Inc. (NASDAQ: NTRA)?

The recent announcement signifies that Natera is working to protect its significant investments in innovation from unlawful infringement by successfully invalidating all three of CareDx’s patents in a related case.

What is the outcome of the infringement lawsuit filed by Natera, Inc. (NASDAQ: NTRA) against CareDx?

The United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents, and the trial will commence on January 22, 2024.

What is the significance of the trial set to begin on January 22, 2024, for Natera, Inc. (NASDAQ: NTRA)?

The trial is significant as Natera aims to protect its significant investments in innovation from unlawful infringement.

What is the impact of the recent court ruling on Natera, Inc. (NASDAQ: NTRA)?

The recent court ruling provides a clear path to trial for Natera as it works to protect its significant investments in innovation from unlawful infringement.